文献速递胸部肿瘤

NGR-hTNF联合研究者选择方案治疗经治恶性胸膜间皮瘤的III期试验

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
PubMed 文献 · Lancet Oncol · 2018-05-09

BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer with highly vascularised tumours. It has poor prognosis and few treatment options after failure of first-line chemotherapy.…

要点

  • NGR-hTNF联合最佳研究者选择未改善经治恶性胸膜间皮瘤的总生存。
  • NGR-hTNF组3级及以上不良事件发生率70%,高于安慰剂组的61%。
  • 亚组分析结果仅为假设生成性,需确证性随机试验验证。

核心结论

  • NGR-hTNF联合最佳研究者选择方案未达到改善总生存的主要终点。

研究设计与样本

  • 随机双盲安慰剂对照III期试验,在12国41中心开展,纳入400例经一线培美曲塞方案后进展的恶性胸膜间皮瘤患者。
  • 最佳研究者选择在随机前确定,可为吉西他滨、长春瑞滨、多柔比星单药或仅最佳支持治疗。

主要发现

  • 3级及以上研究相关不良事件在NGR-hTNF组136例(70%)、安慰剂组118例(61%),最常见为中性粒细胞减少(35例[18%] vs 36例[19%])、疼痛(11例[6%] vs 16例[8%])、呼吸困难(9例[5%] vs 7例[4%])和寒战(9例[5%] vs 0例)。
  • 严重不良事件在NGR-hTNF组50例(26%)、安慰剂组47例(24%);治疗相关严重不良事件分别为17例(9%)和20例(10%)。
  • NGR-hTNF组12例死亡、安慰剂组13例死亡,均与治疗无关。

临床怎么用

  • 不推荐在经治恶性胸膜间皮瘤中常规使用NGR-hTNF联合最佳研究者选择方案。
  • 亚组分析提示快速进展患者可能获益,但需确证性随机试验验证后方可用于临床决策。

局限性

  • 亚组分析结果为假设生成性,未预设确证性检验。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer with highly vascularised tumours. It has poor prognosis and few treatment options after failure of first-line chemotherapy. NGR-hTNF is a vascular-targeting drug that increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment. In this trial, we aimed to investigate the efficacy and safety of NGR-hTNF in patients with malignant pleural mesothelioma who had progressed during or after a first-line treatment. METHODS: NGR015 was a randomised, double-blind, placebo-controlled phase 3 trial done in 41 centres in 12 countries. Eligible participants had malignant pleural mesothelioma of any histological subtype (epithelial, sarcomatoid, or mixed), were aged 18 years or older, and had an Eastern Cooperative Oncology Group performance status of 0-2 and radiologically documented progressive disease after one pemetrexed-based chemotherapy regimen. Participants were randomly assigned to receive weekly NGR-hTNF 0·8 μg/m2 intravenously plus best investigator choice (n=200), or placebo plus best investigator choice (n=200). Best investigator choice was decided before random assignment and could be single-agent gemcitabine (1000-1250 mg/m2 intravenously), vinorelbine (25 mg/m2 intravenously or 60 mg/m2 orally), doxorubicin (60-75 mg/m2 intravenously), or best supportive care only. Patients were randomised (1:1) with a block size of four after stratification for performance status and best investigator choice. The primary study endpoint was overall survival in the intention-to-treat population. The trial is closed to new participants and is registered with ClinicalTrials.gov (NCT01098266). FINDINGS: Between April 12, 2010 and Jan 21, 2013, we enrolled 400 eligible participants. 381 (95%) of 400 patients were selected to receive chemotherapy before all participants were randomly assigned to receive NGF-hTNF plus best investigator choice (n=200) or placebo plus best investigator choice (n=200). At the cutoff date (April 29, 2014), the median follow-up was 18·7 months (IQR 15·1-24·4), and overall survival did not differ between the two treatment groups (median 8·5 months [95% CI 7·2-9·9] in the NGR-hTNF group vs 8·0 months [6·6-8·9] in the placebo group; hazard ratio 0·94, 95% CI 0·75-1·18; p=0·58). Grade 3 or worse study-emergent adverse events occurred in 136 (70%) of patients receiving NGR-hTNF versus 118 (61%) of patients receiving placebo, with the most common being neutropenia (35 [18%] of 193 patients vs 36 [19%] of 193 patients), pain (11 [6%] vs 16 [8%]), dyspnoea (nine [5%] vs seven [4%]), and chills (nine [5%] vs none). 50 (26%) patients in the NGR-hTNF group had a serious adverse event, compared with 47 (24%) in the placebo group. Treatment-related serious adverse events occurred in 17 (9%) patients in the NGR-hTNF group and 20 patients (10%) in the placebo group. There were 12 deaths in the NGR-hTNF group and 13 deaths in the placebo group, but none were treatment related. INTERPRETATION: The study did not meet its primary endpoint. The hypothesis-generating findings from the subgroup analyses deserve a confirmatory randomised trial because patients who rapidly progress after first-line treatment have a poor prognosis. FUNDING: MolMed.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gregorc V, Gaafar RM, Favaretto A, et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018. PMID: 29753703. doi:10.1016/S1470-2045(18)30193-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。